The present disclosure relates to medical apparatus, systems, and methods for ablating tissue in a patient. More specifically, the present disclosure relates to medical apparatus, systems, and methods for ablation of tissue by electroporation.
Ablation procedures are used to treat many different conditions in patients. Ablation may be used to treat cardiac arrhythmias, benign tumors, cancerous tumors, and to control bleeding during surgery. Usually, ablation is accomplished through thermal ablation techniques including radio-frequency (RF) ablation and cryoablation. In RF ablation, a probe is inserted into the patient and radio frequency waves are transmitted through the probe to the surrounding tissue. The radio frequency waves generate heat, which destroys surrounding tissue and cauterizes blood vessels. In cryoablation, a hollow needle or cryoprobe is inserted into the patient and cold, thermally conductive fluid is circulated through the probe to freeze and kill the surrounding tissue. RF ablation and cryoablation techniques indiscriminately kill tissue through cell necrosis, which may damage or kill otherwise healthy tissue, such as tissue in the esophagus, phrenic nerve cells, and tissue in the coronary arteries.
Another ablation technique uses electroporation. In electroporation, or electro-permeabilization, an electric field is applied to cells to increase the permeability of the cell membrane. The electroporation may be reversible or irreversible, depending on the strength of the electric field. If the electroporation is reversible, the increased permeability of the cell membrane may be used to introduce chemicals, drugs, and/or deoxyribonucleic acid (DNA) into the cell, prior to the cell healing and recovering. If the electroporation is irreversible, the affected cells are killed through apoptosis.
Irreversible electroporation (IRE) may be used as a nonthermal ablation technique. In IRE, trains of short, high voltage pulses are used to generate electric fields that are strong enough to kill cells through apoptosis. In ablation of cardiac tissue, IRE may be a safe and effective alternative to the indiscriminate killing of thermal ablation techniques, such as RF ablation and cryoablation. IRE may be used to kill targeted tissue, such as myocardium tissue, by using an electric field strength and duration that kills the targeted tissue but does not permanently damage other cells or tissue, such as non-targeted myocardium tissue, red blood cells, vascular smooth muscle tissue, endothelium tissue, and nerve cells.
As recited in examples, Example 1 is an electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system comprises an ablation catheter including: catheter electrodes configured to generate electric fields in the targeted tissue in response to a plurality of electrical pulse sequences delivered in a plurality of therapy sections; a controller configured to: receive a first pulse voltage of a first electrical pulse sequence measured during a first therapy section of the plurality of therapy sections; determine a charge voltage based on the first pulse voltage; and an electroporation generator. The electroporation generator is operatively coupled to the catheter electrodes and the controller and configured to deliver a second electrical pulse sequence at a controlled pulse voltage for a second therapy section of the plurality of therapy sections, the second therapy section being after the first therapy section, the controlled pulse voltage being associated with the charge voltage.
Example 2 is the electroporation ablation system of Example 1, wherein the electroporation generator comprises a capacitor bank and the electroporation generator is configured to charge the capacitor bank to a voltage level of the charge voltage before a start of the second therapy section.
Example 3 is the electroporation ablation system of Example 1 or 2, wherein the first electrical pulse sequence comprises a plurality of first electrical pulses.
Example 4 is the electroporation ablation system of Example 3, wherein the first pulse voltage comprises one or more pulse voltages of the plurality of first electrical pulses measured during the first therapy section.
Example 5 is the electroporation ablation system of any one of Examples 1-4, wherein the controller is further configured to receive a first pulse current of the first electrical pulse sequence delivered during the first therapy section, wherein the controller is further configured to determine the charge voltage based on the first pulse voltage and the first pulse current.
Example 6 is the electroporation ablation system of Example 5, wherein the controller is further configured to determine a first tissue impedance based on the first pulse voltage and the first pulse current.
Example 7 is the electroporation ablation system of Example 6, wherein the controlled pulse voltage is a portion of the charge voltage.
Example 8 is the electroporation ablation system of Example 7, wherein a ratio of the controlled pulse voltage and the charge voltage is associated with the first tissue impedance.
Example 9 is the electroporation ablation system of any one of Examples 1-8, wherein the electroporation generator is further configured to deliver a scan electrical pulse sequence at a scan voltage during a scan section prior to the plurality of therapy sections, wherein the controller is further configured to determine an initial tissue impedance based on an initial pulse voltage of the scan electrical pulse sequence and an initial pulse current of the scan electrical pulse sequence measured during the scan section, wherein the controller is further configured to determine an initial charge voltage based on the initial tissue impedance.
Example 10 is the electroporation ablation system of Example 9, wherein the scan voltage is less than the controlled pulse voltage.
Example 11 is the electroporation ablation system of Example 9, wherein the scan electrical pulse sequence includes a single non-ablative electrical pulse.
Example 12 is method of using an electroporation ablation device. The method includes the steps of: disposing a catheter of the electroporation ablation device anatomically proximate to a target ablation location, the catheter comprising one or more catheter electrodes and configured to generate electric fields in response to a plurality of electrical pulse sequences delivered in a plurality of therapy sections; receiving a first pulse voltage of a first electrical pulse sequence measured during a first therapy section of the plurality of therapy sections; determining a charge voltage based on the first pulse voltage; and delivering a second electrical pulse sequence at a controlled pulse voltage for a second therapy section of the plurality of therapy sections, the second therapy section being after the first therapy section, the controlled pulse voltage being associated with the charge voltage.
Example 13 is the method of Example 12, further comprising: receiving a first pulse current of first electrical pulse sequence measured during the first therapy section, wherein determining a charge voltage comprises determining the charge voltage based on the first pulse voltage and the first pulse current.
Example 14 is the method of Example 13, further comprising: determining a first tissue impedance based on the first pulse voltage and the first pulse current, wherein determining a charge voltage comprises determining the charge voltage based on the first tissue impedance.
Example 15 is the method of any one of Examples 12-14, further comprising: delivering a scan electrical pulse sequence during a scan section; receiving an initial pulse voltage of the scan electrical pulse sequence measured during the scan section; receiving an initial pulse current of the scan electrical pulse sequence measured during the scan section; and determining an initial tissue impedance based on the initial pulse voltage and the initial pulse current measured, wherein the scan section is before the first therapy section, wherein the scan electrical pulse sequence is at a scan pulse voltage lower than the controlled pulse voltage.
Example 16 is an electroporation ablation system for treating targeted tissue in a patient. The electroporation ablation system comprising: an ablation catheter including: catheter electrodes configured to generate electric fields in the targeted tissue in response to a plurality of electrical pulse sequences delivered in a plurality of therapy sections; a controller configured to receive a first pulse voltage of a first electrical pulse sequence measured during a first therapy section of the plurality of therapy sections; determine a charge voltage based on the first pulse voltage; and an electroporation generator. The electroporation generator is operatively coupled to the catheter electrodes and the controller and configured to deliver a second electrical pulse sequence at a controlled pulse voltage for a second therapy section of the plurality of therapy sections, the second therapy section being after the first therapy section, the controlled pulse voltage being associated with the charge voltage.
Example 17 is the electroporation ablation system of Example 16, wherein the electroporation generator comprises a capacitor bank and the electroporation generator is configured to charge the capacitor bank to a voltage level of the charge voltage before a start of the second therapy section.
Example 18 is the electroporation ablation system of Example 16, wherein the first electrical pulse sequence comprises a plurality of first electrical pulses.
Example 19 is the electroporation ablation system of Example 18, wherein the first pulse voltage comprises one or more pulse voltages of the plurality of first electrical pulses measured during the first therapy section.
Example 20 is the electroporation ablation system of Example 16, wherein the controller is further configured to receive a first pulse current of a first electrical pulse sequence delivered during the first therapy section, wherein the controller is further configured to determine the charge voltage based on the first pulse voltage and the first pulse current.
Example 21 is the electroporation ablation system of Example 20, wherein the controller is further configured to determine a first tissue impedance based on the first pulse voltage and the first pulse current.
Example 22 is the electroporation ablation system of Example 21, wherein the controlled pulse voltage is a portion of the charge voltage.
Example 23 is the electroporation ablation system of Example 22, wherein a ratio of the controlled pulse voltage and the charge voltage is associated with the first tissue impedance.
Example 24 is the electroporation ablation system of Example 16, wherein the electroporation generator is further configured to deliver a scan electrical pulse sequence at a scan voltage during a scan section prior to the plurality of therapy sections, wherein the controller is further configured to determine an initial tissue impedance based on an initial pulse voltage of the scan electrical pulse sequence and an initial pulse current of the scan electrical pulse sequence measured during the scan section, wherein the controller is further configured to determine an initial charge voltage based on the initial tissue impedance.
Example 25 is the electroporation ablation system of Example 24, wherein the scan voltage is less than the controlled pulse voltage.
Example 26 is the electroporation ablation system of Example 24, wherein the scan electrical pulse sequence includes a single non-ablative electrical pulse.
Example 27 is the electroporation ablation system of Example 16, wherein the electroporation generator comprises a plurality of capacitor banks, wherein the electroporation generator is configured to charge at least one of the plurality of capacitor banks to a voltage level individually.
Example 28 is the electroporation ablation system of Example 27, wherein the electroporation generator is configured to use a first capacitor bank of the plurality of capacitor banks to deliver a pulse sequence for a specific therapy section of the plurality of therapy sections and charge a second capacitor bank of the plurality of capacitor banks to a voltage level of a determined charge voltage before a start of a therapy section immediately after the specific therapy section of the plurality of therapy sections.
Example 29 is the electroporation ablation system of Example 27, wherein the catheter electrodes comprise a plurality of electrode pairs, wherein each capacitor bank of the plurality of capacitor banks is operatively coupled to one or more electrode pairs of the plurality of electrode pairs.
Example 30 is the electroporation ablation system of Example 29, wherein the controller is configured to determine a bank charge voltage for each capacitor bank of the plurality of capacitor banks.
Example 31 is a method of using an electroporation ablation device. The method includes the step of: disposing a catheter of the electroporation ablation device anatomically proximate to a target ablation location, the catheter comprising one or more catheter electrodes and configured to generate electric fields in response to a plurality of electrical pulse sequences delivered in a plurality of therapy sections; receiving a first pulse voltage of a first electrical pulse sequence measured during a first therapy section of the plurality of therapy sections; determining a charge voltage based on the first pulse voltage; and delivering a second electrical pulse sequence at a controlled pulse voltage for a second therapy section of the plurality of therapy sections, the second therapy section being after the first therapy section, the controlled pulse voltage being associated with the charge voltage.
Example 32 is the method of Example 31, further comprising: receiving a first pulse current of first electrical pulse sequence measured during the first therapy section, wherein determining a charge voltage comprises determining the charge voltage based on the first pulse voltage and the first pulse current.
Example 33 is the method of Example 32, further comprising: determining a first tissue impedance based on the first pulse voltage and the first pulse current, wherein determining a charge voltage comprises determining the charge voltage based on the first tissue impedance.
Example 34 is the method of Example 30, further comprising: delivering a scan electrical pulse sequence during a scan section; receiving an initial pulse voltage of the scan electrical pulse sequence measured during the scan section; receiving an initial pulse current of the scan electrical pulse sequence measured during the scan section; and determining an initial tissue impedance based on the initial pulse voltage and the initial pulse current measured, wherein the scan section is before the first therapy section, wherein the scan electrical pulse sequence is at a scan pulse voltage lower than the controlled pulse voltage.
Example 35 is the method of Example 34, wherein the scan pulse voltage is at a non-ablative voltage level.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
As the terms are used herein with respect to measurements (e.g., dimensions, characteristics, attributes, components, etc.), and ranges thereof, of tangible things (e.g., products, inventory, etc.) and/or intangible things (e.g., data, electronic representations of currency, accounts, information, portions of things (e.g., percentages, fractions), calculations, data models, dynamic system models, algorithms, parameters, etc.), “about” and “approximately” may be used, interchangeably, to refer to a measurement that includes the stated measurement and that also includes any measurements that are reasonably close to the stated measurement, but that may differ by a reasonably small amount such as will be understood, and readily ascertained, by individuals having ordinary skill in the relevant arts to be attributable to measurement error; differences in measurement and/or manufacturing equipment calibration; human error in reading and/or setting measurements; adjustments made to optimize performance and/or structural parameters in view of other measurements (e.g., measurements associated with other things); particular implementation scenarios; imprecise adjustment and/or manipulation of things, settings, and/or measurements by a person, a computing device, and/or a machine; system tolerances; control loops; machine-learning; foreseeable variations (e.g., statistically insignificant variations, chaotic variations, system and/or model instabilities, etc.); preferences; and/or the like.
Although illustrative methods may be represented by one or more drawings (e.g., flow diagrams, communication flows, etc.), the drawings should not be interpreted as implying any requirement of, or particular order among or between, various steps disclosed herein. However, certain some embodiments may require certain steps and/or certain orders between certain steps, as may be explicitly described herein and/or as may be understood from the nature of the steps themselves (e.g., the performance of some steps may depend on the outcome of a previous step). Additionally, a “set,” “subset,” or “group” of items (e.g., inputs, algorithms, data values, etc.) may include one or more items, and, similarly, a subset or subgroup of items may include one or more items. A “plurality” means more than one.
As used herein, the term “based on” is not meant to be restrictive, but rather indicates that a determination, identification, prediction, calculation, and/or the like, is performed by using, at least, the term following “based on” as an input. For example, predicting an outcome based on a particular piece of information may additionally, or alternatively, base the same determination on another piece of information.
Cryo energy and radio-frequency (RF) energy kill tissues indiscriminately through cell necrosis, which can damage the esophagus, the phrenic nerve, coronary arteries, in addition to other undesired effects. Irreversible electroporation (IRE) uses high voltage, short (e.g., 100 microseconds or shorter) pulses to kill cells through apoptosis. IRE can be targeted to kill myocardium, sparing other adjacent tissues including the esophageal vascular smooth muscle and endothelium. After IRE ablation commences, pore are induced in cell membranes and intracellular fluids are released into the extracellular matrix, such that tissue conductivity is increased and tissue impedance is decreased. Changes in tissue impedance occur rapidly, within the course of multiple IRE therapy sections, also referred to as therapy bursts or therapy sections. A therapy section (e.g., for a duration of 10 milliseconds) may include a plurality of electrical pulses (e.g., 20 pulses, 30 pulses, etc.) generated and delivered by an electroporation generator. If the electroporation generator does not adjust its charge voltage provided by source component(s), the therapeutic pulse voltage drops over the course of the IRE ablation by as much as 40%. Since the IRE treatment depends on the electric field, the drop of the pulse voltage can potentially impact the effectiveness of the IRE treatment.
The present disclosure describes systems, devices and methods for implementing ablation with voltage controlled electrical pulse sequences. In some embodiments, the pulse voltage and/or pulse current are measured during therapy sections and used to determine a charge voltage for the next therapy section, such that electrical pulses each has a voltage close to a target pulse voltage during the next therapy section. As used herein, the charge voltage refers to the voltage generated by the electroporation generator, which can be the voltage of one or more capacitor banks or other power source. In some embodiments, the tissue impedance is computed based on the pulse voltage and pulse current. In some cases, the tissue impedance is used to determine the charge voltage.
In some embodiments, the catheter(s) 110 can be various types and forms of electroporation catheter such as, for example, linear ablation catheters, focal ablation catheters, circumferential catheters, and/or the like. In embodiments, the electroporation ablation system 100 includes an introducer sheath (not shown) operable to provide a delivery conduit through which the electroporation ablation catheter 110 can be deployed to specific target sites within a patient's cardiac chamber. In some cases, the electroporation ablation catheter 110 includes a shaft having a distal end and catheter electrodes situated at the distal end of the shaft and spatially arranged to generate electric fields in the targeted tissue in response to a plurality of electrical pulse sequences delivered in a plurality of therapy sections. In some cases, the catheter(s) 110 include deflectable catheter(s).
In some cases, the catheter(s) 110 includes one or more electrodes to generate an electric field for ablation. The electroporation generator 140, also referred to as a pulse generator, is configured to generate ablative pulse/energy, or referred to as electroporation pulse/energy, to be delivered to electrodes of the catheter(s) 110. The electroporation pulse is typically high voltage and short pulse. The controller 120 is configured to control functional aspects of the electroporation ablation system 100. In embodiments, the electroporation controller 120 is configured to control the electroporation generator 140 on the generation and delivery of ablative energy to electrodes of the catheter(s) 110 is individually addressable. In one case, each of the one or more electrodes of the catheter(s) 110. In such case, the controller 120 may control the ablative energy delivery to each electrode.
In some embodiments, the electroporation controller 120 can control an output voltage (i.e. the pulse voltage of pulse sequences) generated by the electroporation generator 140. In some embodiments, the electroporation generator 140 includes a capacitor bank 145, which can be charged and discharged for the generation of the charge voltage to generate electrical pulses. In some cases, the electroporation controller 120 can determine a charge voltage of the capacitor bank 145 in response to the sensing data. In some implementations, the charge voltage is the voltage generated by the electricity source component(s) (e.g., the capacitor bank 145) of the electroporation generator 140. In some cases, the capacitor bank 145 includes one or more capacitor banks such that at least one capacitor bank is to provide the charge voltage for the current therapy section (e.g., the current therapy burst) of the electrical pulses and at least one capacitor bank is to be charged for providing the charge voltage for the next therapy section (e.g., the next therapy burst) of electrical pulses. In some embodiments, the electroporation generator 140 has an internal impedance, or referred to as generator impedance. In some cases, the electroporation generator 140 can generate electrical pulses at a pulse voltage, or referred to as an output voltage, which is lower than the charge voltage because of the generator impedance. In some cases, the pulse voltage is a portion of the charge voltage. In some cases, a user can set up a target pulse voltage via an interface to the controller (e.g., a user interface, a software interface, a system interface).
In some embodiments, the electroporation controller 120 receives sensor data collected by sensor(s) of catheter(s) and/or sensors 130 placed proximate to the ablation location. In some cases, the controller 120 is configured to determine a tissue impedance based upon the measured pulse voltage and/or pulse current proximate to the electroporation location. In some cases, the controller 120 is configured to determine a charge voltage based on the measured pulse voltage and/or the tissue impedance. In some cases, the controller 120 is configured to determine a charge voltage based on the target pulse voltage, the generator impedance, and/or the tissue impedance. In some cases, the controller 120 is configured to control the capacitor bank 145 based on the determined charge voltage.
In some embodiments, the controller 120 is configured to receive a first pulse voltage and/or a first pulse current of a first electrical pulse sequence delivered during a first therapy section of a plurality of therapy sections. In some implementations, an electrical pulse sequence includes a plurality of the electrical/electroporation pulses for a therapy section. In some cases, the first pulse voltage and/or the first pulse current are measured for a last electrical pulse in a therapy section. In some cases, the first pulse voltage and/or the first pulse current are measured for a first electrical pulse in a therapy section. In some cases, the first pulse voltage and/or the first pulse current are determined based on measurements of a plurality of electrical pulses in a therapy section. In one example, the first pulse voltage and/or the first pulse current are an average voltage and/or current measured for a plurality of electrical pulses in a therapy section respectively. In one example, the first pulse voltage and/or the first pulse current are an average voltage and/or current measured for all the electrical pulses in the therapy section respectively.
In some embodiments, the controller 120 determines a charge voltage based on the first pulse voltage. In some cases, the controller 120 determines a charge voltage difference between the determined charge voltage and the current charge level of the capacitor bank 145. In some cases, the controller 120 determines a charge voltage difference based on a percentage difference between the measured pulse voltage and the target pulse voltage. For example, the charge voltage difference is determined by the current charge voltage multiplied by a percentage difference between the measured pulse voltage and the target pulse voltage. In some cases, the controller 120 controls or sets the capacitor bank 145 based on the determined charge voltage and/or the charge voltage difference. In some embodiments, the electroporation generator 140 is operatively coupled to the catheter electrodes and the controller 120 and configured to deliver a second electrical pulse sequence at a controlled pulse voltage for a second therapy section of the plurality of therapy sections, where the second therapy section is after the first therapy section. In some cases, the controlled pulse voltage is based at least in part on a determined charge voltage. In some cases, the capacitor bank 145 is set at the level of the determined charge voltage.
In some embodiments, the controller 120 is configured to determine the charge voltage for the second therapy section based on the first pulse voltage and the first pulse current. In some cases, the controller 120 is configured to determine a first tissue impedance based on the first pulse voltage and the first pulse current. In some cases, the controller 120 is configured to determine the charge voltage based on the first tissue impedance and the target pulse voltage. In some cases, the controller 120 is configured to determine the charge voltage based on the first tissue impedance, the target pulse voltage, and the generator impedance. In some embodiments, the electroporation generator 140 is configured to receive the signal indicative of the determined charge voltage and charge the capacitor bank 145 to the level of the determined charged voltage before the start of the next therapy section. In some cases, the controlled pulse voltage is a portion of the determined charge voltage. In some cases, the ratio of the controlled pulse voltage and the determined charge voltage is associated with the first tissue impedance.
In embodiments, the controller 120 is configured to measure pulse voltages and/or pulse currents during each or some of the therapy sections to determine the charge voltages for the subsequent therapy sections. In some embodiments, the controller 120 is configured to store pulse voltages, pulse currents, charge voltages, generator impedance(s), and/or tissue impedances in the data repository 165.
In some embodiments, the electroporation generator 140 is configured to deliver a scan electrical pulse sequence at a scan voltage during a scan section prior to the plurality of therapy sections, where the scan voltage is lower than the therapeutic voltage (e.g., the target pulse voltage). In some cases, the scan voltage is a non-ablative voltage level. In some cases, the scan electrical pulse sequence is a single non-ablative electrical pulse. In some cases, the controller 120 is configured to determine an initial tissue impedance based on an initial pulse voltage of the scan electrical pulse sequence and an initial pulse current of the scan electrical pulse sequence measured during the scan section. In some cases, the controller 120 is configured to determine an initial charge voltage based on the initial tissue impedance. In some cases, the controller 120 is configured to determine an initial charge voltage based on the initial tissue impedance and the target pulse voltage. In some cases, the controller 120 is configured to determine an initial charge voltage based on the initial tissue impedance, the target pulse voltage, and the generator impedance.
In some embodiments, the catheter 110 includes two or more electrode pairs of and the capacitor bank 145 includes two or more capacitor banks, where each capacitor bank in the capacitor bank 145 (e.g., a group of capacitor banks) is configured to charge one or more electrode pairs. In some cases, the electroporation controller 120 is configured to receive measured pulse voltages from the electrode pairs and determine a charge voltage for each respective capacitor bank for charging the electrode pairs. By way of an example, the capacitor bank 145 includes two capacitor banks (e.g., Bank A, Bank B), each capacitor bank is configured to charge two electrode pairs (e.g., Bank A for charging Electrode Pairs 1 & 2, Bank B for charging Electrode Pairs 3 & 4). In this example, the electroporation controller 120 is configured to determine a charge voltage for Bank A based on the measured pulse voltage of the Electrode Pairs 1 & 2, and determine a charge voltage for Bank B based on the measured pulse voltage of the Electrode Pairs 3 & 4.
In embodiments, the electroporation controller 120 includes one or more controllers, microprocessors, and/or computers that execute code out of memory 160, for example, non-transitory machine readable medium, to control and/or perform the functional aspects of the electroporation ablation system 100. In embodiments, the memory 160 can be part of the one or more controllers, microprocessors, and/or computers, and/or part of memory capacity accessible through a network, such as the world wide web. In embodiments, the memory 160 comprises a data repository 165, which is configured to store ablation data (e.g., location, energy, etc.), measured pulse voltages, measured pulse currents, tissue impedances, generator impedance, sensed data, treatment plan data, charge voltages, and/or the like.
In embodiments, the other systems 170 includes an electro-anatomical mapping (EAM) system. In some cases, the EAM system is operable to track the location of the various functional components of the electroporation ablation system 100, and to generate high-fidelity three-dimensional anatomical and electro-anatomical maps of the cardiac chambers of interest. In embodiments, the EAM system can be the RHYTHMIA™ HDx mapping system marketed by Boston Scientific Corporation. Also, in embodiments, the mapping and navigation controller of the EAM system includes one or more controllers, microprocessors, and/or computers that execute code out of memory to control and/or perform functional aspects of the EAM system.
The EAM system generates a localization field, via a field generator, to define a localization volume about the heart, and one or more location sensors or sensing elements on the tracked device(s), e.g., the electroporation ablation catheter 110, generate an output that can be processed by a mapping and navigation controller to track the location of the sensor, and consequently, the corresponding device, within the localization volume. In one embodiment, the device tracking is accomplished using magnetic tracking techniques, whereby the field generator is a magnetic field generator that generates a magnetic field defining the localization volume, and the location sensors on the tracked devices are magnetic field sensors.
In some embodiments, impedance tracking methodologies may be employed to track the locations of the various devices. In such embodiments, the localization field is an electric field generated, for example, by an external field generator arrangement, e.g., surface electrodes, by intra-body or intra-cardiac devices, e.g., an intracardiac catheter, or both. In these embodiments, the location sensing elements can constitute electrodes on the tracked devices that generate outputs received and processed by the mapping and navigation controller to track the location of the various location sensing electrodes within the localization volume.
In embodiments, the EAM system is equipped for both magnetic and impedance tracking capabilities. In such embodiments, impedance tracking accuracy can, in some instances be enhanced by first creating a map of the electric field induced by the electric field generator within the cardiac chamber of interest using a probe equipped with a magnetic location sensor, as is possible using the aforementioned RHYTHMIA HDx™ mapping system. One exemplary probe is the INTELLAMAP ORION™ mapping catheter marketed by Boston Scientific Corporation.
Regardless of the tracking methodology employed, the EAM system utilizes the location information for the various tracked devices, along with cardiac electrical activity acquired by, for example, the electroporation ablation catheter 110 or another catheter or probe equipped with sensing electrodes, to generate, and display via a display, detailed three-dimensional geometric anatomical maps or representations of the cardiac chambers as well as electro-anatomical maps in which cardiac electrical activity of interest is superimposed on the geometric anatomical maps. Furthermore, the EAM system can generate a graphical representation of the various tracked devices within the geometric anatomical map and/or the electro-anatomical map.
According to embodiments, various components (e.g., the controller 120) of the electroporation ablation system 100 may be implemented on one or more computing devices. A computing device may include any type of computing device suitable for implementing embodiments of the disclosure. Examples of computing devices include specialized computing devices or general-purpose computing devices such as workstations, servers, laptops, portable devices, desktop, tablet computers, hand-held devices, general-purpose graphics processing units (GPGPUs), and the like, all of which are contemplated within the scope of
In some embodiments, a computing device includes a bus that, directly and/or indirectly, couples the following devices: a processor, a memory, an input/output (I/O) port, an I/O component, and a power supply. Any number of additional components, different components, and/or combinations of components may also be included in the computing device. The bus represents what may be one or more busses (such as, for example, an address bus, data bus, or combination thereof). Similarly, in some embodiments, the computing device may include a number of processors, a number of memory components, a number of I/O ports, a number of I/O components, and/or a number of power supplies. Additionally, any number of these components, or combinations thereof, may be distributed and/or duplicated across a number of computing devices.
In some embodiments, the memory 160 includes computer-readable media in the form of volatile and/or nonvolatile memory, transitory and/or non-transitory storage media and may be removable, nonremovable, or a combination thereof. Media examples include Random Access Memory (RAM); Read Only Memory (ROM); Electronically Erasable Programmable Read Only Memory (EEPROM); flash memory; optical or holographic media; magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices; data transmissions; and/or any other medium that can be used to store information and can be accessed by a computing device such as, for example, quantum state memory, and/or the like. In some embodiments, the memory 160 stores computer-executable instructions for causing a processor (e.g., the controller 120) to implement aspects of embodiments of system components discussed herein and/or to perform aspects of embodiments of methods and procedures discussed herein.
Computer-executable instructions may include, for example, computer code, machine-useable instructions, and the like such as, for example, program components capable of being executed by one or more processors associated with a computing device. Program components may be programmed using any number of different programming environments, including various languages, development kits, frameworks, and/or the like. Some or all of the functionality contemplated herein may also, or alternatively, be implemented in hardware and/or firmware.
The data repository 165 may be implemented using any one of the configurations described below. A data repository may include random access memories, flat files, XML files, and/or one or more database management systems (DBMS) executing on one or more database servers or a data center. A database management system may be a relational (RDBMS), hierarchical (HDBMS), multidimensional (MDBMS), object oriented (ODBMS or OODBMS) or object relational (ORDBMS) database management system, and the like. The data repository may be, for example, a single relational database. In some cases, the data repository may include a plurality of databases that can exchange and aggregate data by data integration process or software application. In an exemplary embodiment, at least part of the data repository 165 may be hosted in a cloud data center. In some cases, a data repository may be hosted on a single computer, a server, a storage device, a cloud server, or the like. In some other cases, a data repository may be hosted on a series of networked computers, servers, or devices. In some cases, a data repository may be hosted on tiers of data storage devices including local, regional, and central.
Various components of the system 100 can communicate via or be coupled to via a communication interface, for example, a wired or wireless interface. The communication interface includes, but not limited to, any wired or wireless short-range and long-range communication interfaces. The wired interface can use cables, umbilicals, and the like. The short-range communication interfaces may be, for example, local area network (LAN), interfaces conforming known communications standard, such as Bluetooth® standard, IEEE 802 standards (e.g., IEEE 802.11), a ZigBee® or similar specification, such as those based on the IEEE 802.15.4 standard, or other public or proprietary wireless protocol. The long-range communication interfaces may be, for example, wide area network (WAN), cellular network interfaces, satellite communication interfaces, etc. The communication interface may be either within a private computer network, such as intranet, or on a public computer network, such as the internet.
In some embodiments, during a therapy section, a pulse_voltage or a plurality of pulse voltages are measured. In one example, the pulse_voltage 420 has a relation with the charge_voltage 410 represented in equation (1) below:
where VoltagePulse is the pulse_voltage 420, Voltagecharge is the charge_voltage 410, ImpedanceTissue represents the tissue impedance 440, and ImpedanceGenerator is the generator impedance 437. Additionally, in one example, the charge_voltage 410 can be determined by the pulse_voltage 420 measured during the therapy sections, according the equation (2) below:
where VoltageCharge is the voltage generated from the voltage source 432 and the bulk capacitance 435, VoltagePulse is the pulse_voltage 420, ImpedanceTissue represents the tissue impedance 440, and ImpedanceGenerator is the generator impedance 437.
In some embodiments, a controller (e.g., the controller 120 of
Electrodes in the first group of electrodes 208 are spaced apart from electrodes in the second group of electrodes 210. The first group of electrodes 208 includes electrodes 208a-208f and the second group of electrodes 210 includes electrodes 210a-210f. Also, electrodes in the first group of electrodes 208, such as electrodes 208a-208f, are spaced apart from one another and electrodes in the second of electrodes 210, such as electrodes 210a-210f, are spaced apart from one another.
The spatial relationships and orientation of the electrodes in the first group of electrodes 208 and the spatial relationships and orientation of the electrodes in the second group of electrodes 210 in relation to other electrodes on the same catheter 200 is known or can be determined. In embodiments, the spatial relationships and orientation of the electrodes in the first group of electrodes 208 and the spatial relationships and orientation of the electrodes in the second group of electrodes 210 in relation to other electrodes on the same catheter 200 is constant, once the catheter is deployed.
As to electric fields, in embodiments, each of the electrodes in the first group of electrodes 208 and each of the electrodes in the second group of electrodes 210 can be selected to be an anode or a cathode, such that electric fields can be set up between any two or more of the electrodes in the first and second groups of electrodes 208 and 210. Also, in embodiments, each of the electrodes in the first group of electrodes 208 and each of the electrodes in the second group of electrodes 210 can be selected to be a biphasic pole, such that the electrodes switch or take turns between being an anode and a cathode. Also, in embodiments, groups of the electrodes in the first group of electrodes 208 and groups of the electrodes in the second group of electrodes 210 can be selected to be an anode or a cathode or a biphasic pole, such that electric fields can be set up between any two or more groups of the electrodes in the first and second groups of electrodes 208 and 210.
In embodiments, electrodes in the first group of electrodes 208 and the second group of electrodes 210 can be selected to be biphasic pole electrodes, such that during a pulse train including a biphasic pulse train, the selected electrodes switch or take turns between being an anode and a cathode, and the electrodes are not relegated to monophasic delivery where one is always an anode and another is always a cathode. In some cases, the electrodes in the first and second group of electrodes 208 and 210 can form electric fields with electrode(s) of another catheter. In such cases, the electrodes in the first and second group of electrodes 208 and 210 can be anodes of the fields, or cathodes of the fields.
Further, as described herein, the electrodes are selected to be one of an anode and a cathode, however, it is to be understood without stating it that throughout this disclosure the electrodes can be selected to be biphasic poles, such that they switch or take turns between being anodes and cathodes. In some cases, one or more of the electrodes in the first group of electrodes 208 are selected to be cathodes and one or more of the electrodes in the second group of electrodes 210 are selected to be anodes. Also, in embodiments, one or more of the electrodes in the first group of electrodes 208 can be selected as a cathode and another one or more of the electrodes in the first group of electrodes 208 can be selected as an anode. In embodiments, one or more of the electrodes in the second group of electrodes 210 can be selected as a cathode and another one or more of the electrodes in the second group of electrodes 210 can be selected as an anode.
Electrodes in the first group of electrodes 258 are spaced apart from electrodes in the second group of electrodes 260. The first group of electrodes 258 includes electrodes 258a-258f and the second group of electrodes 260 includes electrodes 260a-260f. Also, electrodes in the first group of electrodes 258, such as electrodes 258a-258f, are spaced apart from one another and electrodes in the second of electrodes 260, such as electrodes 260a-260f, are spaced apart from one another.
The spatial relationships and orientation of the electrodes in the first group of electrodes 258 and the spatial relationships and orientation of the electrodes in the second group of electrodes 260 in relation to other electrodes on the same catheter 250 are known or can be determined. In embodiments, the spatial relationships and orientation of the electrodes in the first group of electrodes 258 and the spatial relationships and orientation of the electrodes in the second group of electrodes 260 in relation to other electrodes on the same catheter 250 are variable, where the distal end 262 of the catheter 250 can be extended and retracted which changes the spatial relationships and orientation of the electrodes 258 and 260. In some embodiments, the spatial relationships and orientation of the electrodes in the first group of electrodes 258 and the spatial relationships and orientation of the electrodes in the second group of electrodes 260 on the same catheter 250 is constant, once the catheter 250 is deployed.
As to electric fields, in embodiments, each of the electrodes in the first group of electrodes 258 and each of the electrodes in the second group of electrodes 260 can be selected to be an anode or a cathode, such that electric fields can be set up between any two or more of the electrodes in the first and second groups of electrodes 258 and 260. Also, in embodiments, groups of the electrodes in the first group of electrodes 258 and groups of the electrodes in the second group of electrodes 260 can be selected to be an anode or a cathode, such that electric fields can be set up between any two or more groups of the electrodes in the first and second groups of electrodes 258 and 260. In some cases, the electrodes in the first and second group of electrodes 258 and 260 can form electric fields with electrode(s) of another catheter. In such cases, the electrodes in the first and second group of electrodes 258 and 260 can be anodes of the fields, or cathodes of the fields.
In some embodiments, one or more of the electrodes in the first group of electrodes 258 are selected to be cathodes and one or more of the electrodes in the second group of electrodes 260 are selected to be anodes. Also, in embodiments, one or more of the electrodes in the first group of electrodes 258 can be selected as a cathode and another one or more of the electrodes in the first group of electrodes 258 can be selected as an anode. In addition, in embodiments, one or more of the electrodes in the second group of electrodes 260 can be selected as a cathode and another one or more of the electrodes in the second group of electrodes 260 can be selected as an anode. Using the characteristics of the catheter 250 and the surrounding tissue, an electroporation controller (e.g., the controller 120 of
In some cases, the electroporation ablation system is configured to conduct a scan section to determine an initial tissue impedance (610). In some cases, the scan section is conducted before therapy sections. In some cases, the scan section includes a scan electrical pulse sequence at a scan voltage lower than the therapeutic pulse voltage. In one embodiment, the scan electrical pulse sequence includes a single non-ablative electrical pulse during the scan section. In some embodiments, the initial pulse voltage of the scan electrical pulse sequence and the initial pulse current of the scan electrical pulse sequence are measured during the scan section. In some cases, the initial pulse voltage and the initial pulse current are measured for a last electrical pulse in the scan electrical pulse sequence. In some cases, the initial pulse voltage and/or initial first pulse current is measured for a first electrical pulse of the scan electrical pulse sequence. In some cases, the initial pulse voltage and/or the initial pulse current are determined based on measurements of a plurality of electrical pulses in the scan electrical pulse sequence.
In one example, the initial pulse voltage and/or the initial pulse current are an average voltage and/or current measured for a plurality of electrical pulses in the scan section respectively. In one example, the initial pulse voltage and/or the initial pulse current are an average voltage and/or current measured for all the electrical pulses in the scan section respectively. In some embodiments, the initial tissue impedance is determined to be the initial pulse voltage divided by the initial pulse current. In some cases, the generator impedance can be determined by the charge voltage output from the capacitor bank (e.g., capacitor bank 145 of
In some embodiments, the electroporation ablation system is configured to measure one or more pulse voltages (615), for example, during a therapy section. In some embodiments, the electroporation ablation system is configured to measure one or more pulse currents (620), for example, corresponding to the one or more pulse voltages. In some cases, a controller (e.g., the controller 120 in
In one implementation, the current tissue impedance is determined to be the pulse voltage divided by the pulse current measured at the last electrical pulse during the therapy section. In one implementation, the current tissue impedance is determined to be the pulse voltage divided by the pulse current. In one implementation, the current tissue impedance is determined based on a plurality of pulse voltages and a plurality of pulse currents measured during the therapy section. In some cases, the current tissue impedance is used to determine the charge voltage of the electroporation generator (i.e. the voltage generated by the electroporation generator). In some cases, the pulse voltage and/or pulse current are measured by sensors (e.g., sensors 130 in
In some embodiments, the electroporation ablation system is configured to determine a charge voltage of the electroporation generator (e.g., electroporation generator 140 in
In one embodiment, the electric field generated by electrodes of the deployed catheter(s) has a field strength no higher than 1500 volts per centimeter. In one embodiment, the electric field generated by electrodes of the deployed catheter(s) has a field strength higher than 500 volts per centimeter. In some embodiments, the electroporation ablation system is configured to control the power source based on the determined charge voltage (630), for example, by charging the capacitor bank based on the determined charge voltage. In some embodiments, the electroporation ablation system is configured to set the capacitor bank based on a voltage difference between the determined charge voltage and the current charge voltage of the power source.
In some embodiments, the electroporation ablation system is configured to deliver an electrical pulse sequence (635) for a next therapy section, for example, using the power source. In some cases, if the ablation therapy section has not ended, the electroporation ablation system goes back to step 615 to measure the one or more pulse voltages during the electrical pulse sequence (e.g., a plurality of electrical pulses delivered during a burst period) being delivered. In embodiments, the electroporation ablation system configured to measure pulse voltages and/or pulse currents during each or some of the therapy sections to determine the charge voltages for the subsequent therapy sections.
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present disclosure. For example, while the embodiments described above refer to particular features, the scope of the present disclosure also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
This application claims priority to Provisional Application No. 63/142,133, filed Jan. 27, 2021, which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4200104 | Harris | Apr 1980 | A |
4470407 | Hussein | Sep 1984 | A |
4739759 | Rexroth et al. | Apr 1988 | A |
5234004 | Hascoet et al. | Aug 1993 | A |
5242441 | Avitall | Sep 1993 | A |
5257635 | Langberg | Nov 1993 | A |
5281213 | Milder et al. | Jan 1994 | A |
5304214 | Deford et al. | Apr 1994 | A |
5306296 | Wright et al. | Apr 1994 | A |
5334183 | Wuchinich | Aug 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5342301 | Saab | Aug 1994 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5454370 | Avitall | Oct 1995 | A |
5515848 | Corbett et al. | May 1996 | A |
5531685 | Hemmer et al. | Jul 1996 | A |
5545161 | Imran | Aug 1996 | A |
5578040 | Smith | Nov 1996 | A |
5617854 | Munsif | Apr 1997 | A |
5624430 | Eton et al. | Apr 1997 | A |
5667491 | Pliquett et al. | Sep 1997 | A |
5672170 | Cho et al. | Sep 1997 | A |
5700243 | Narciso, Jr. | Dec 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5706823 | Wodlinger | Jan 1998 | A |
5722400 | Ockuly et al. | Mar 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5749914 | Janssen | May 1998 | A |
5779699 | Lipson | Jul 1998 | A |
5788692 | Campbell et al. | Aug 1998 | A |
5810762 | Hofmann | Sep 1998 | A |
5833710 | Jacobson | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5836942 | Netherly et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5843154 | Osypka | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5863291 | Schaer | Jan 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5895404 | Ruiz | Apr 1999 | A |
5899917 | Edwards et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5916158 | Webster, Jr. | Jun 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5921924 | Avitall | Jul 1999 | A |
5928269 | Alt | Jul 1999 | A |
5928270 | Ramsey, III | Jul 1999 | A |
5938660 | Swartz et al. | Aug 1999 | A |
6002955 | Willems et al. | Dec 1999 | A |
6006131 | Cooper et al. | Dec 1999 | A |
6009351 | Flachman | Dec 1999 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6033403 | Tu et al. | Mar 2000 | A |
6035238 | Ingle et al. | Mar 2000 | A |
6045550 | Simpson et al. | Apr 2000 | A |
6068653 | LaFontaine | May 2000 | A |
6071274 | Thompson et al. | Jun 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6074389 | Levine et al. | Jun 2000 | A |
6076012 | Swanson et al. | Jun 2000 | A |
6090104 | Webster, Jr. | Jul 2000 | A |
6096036 | Bowe et al. | Aug 2000 | A |
6113595 | Muntermann | Sep 2000 | A |
6119041 | Pomeranz et al. | Sep 2000 | A |
6120500 | Bednarek et al. | Sep 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6146381 | Bowe et al. | Nov 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6167291 | Barajas et al. | Dec 2000 | A |
6171305 | Sherman | Jan 2001 | B1 |
6216034 | Hofmann et al. | Apr 2001 | B1 |
6219582 | Hofstad et al. | Apr 2001 | B1 |
6223085 | Dann et al. | Apr 2001 | B1 |
6231518 | Grabek et al. | May 2001 | B1 |
6245064 | Lesh et al. | Jun 2001 | B1 |
6251107 | Schaer | Jun 2001 | B1 |
6251109 | Hassett et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6272384 | Simon et al. | Aug 2001 | B1 |
6287306 | Kroll et al. | Sep 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6350263 | Wetzig et al. | Feb 2002 | B1 |
6370412 | Armoundas et al. | Apr 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6447505 | McGovern et al. | Sep 2002 | B2 |
6464699 | Swanson | Oct 2002 | B1 |
6470211 | Ideker et al. | Oct 2002 | B1 |
6502576 | Lesh | Jan 2003 | B1 |
6503247 | Swartz et al. | Jan 2003 | B2 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6527724 | Fenici | Mar 2003 | B1 |
6527767 | Wang et al. | Mar 2003 | B2 |
6592581 | Bowe | Jul 2003 | B2 |
6595991 | Toellner et al. | Jul 2003 | B2 |
6607520 | Keane | Aug 2003 | B2 |
6613046 | Jenkins et al. | Sep 2003 | B1 |
6623480 | Kuo et al. | Sep 2003 | B1 |
6638278 | Falwell et al. | Oct 2003 | B2 |
6666863 | Wentzel et al. | Dec 2003 | B2 |
6669693 | Friedman | Dec 2003 | B2 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6719756 | Muntermann | Apr 2004 | B1 |
6723092 | Brown et al. | Apr 2004 | B2 |
6728563 | Rashidi | Apr 2004 | B2 |
6743225 | Sanchez et al. | Jun 2004 | B2 |
6743226 | Cosman et al. | Jun 2004 | B2 |
6743239 | Kuehn et al. | Jun 2004 | B1 |
6764486 | Natale | Jul 2004 | B2 |
6780181 | Kroll et al. | Aug 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6807447 | Griffin, III | Oct 2004 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6893438 | Hall et al. | May 2005 | B2 |
6926714 | Sra | Aug 2005 | B1 |
6955173 | Lesh | Oct 2005 | B2 |
6960206 | Keane | Nov 2005 | B2 |
6960207 | Vanney et al. | Nov 2005 | B2 |
6972016 | Hill et al. | Dec 2005 | B2 |
6973339 | Govari | Dec 2005 | B2 |
6979331 | Hintringer et al. | Dec 2005 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
6985776 | Kane et al. | Jan 2006 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7041095 | Wang et al. | May 2006 | B2 |
7113831 | Hooven | Sep 2006 | B2 |
7171263 | Darvish et al. | Jan 2007 | B2 |
7182725 | Bonan et al. | Feb 2007 | B2 |
7195628 | Falkenberg | Mar 2007 | B2 |
7207988 | Leckrone et al. | Apr 2007 | B2 |
7207989 | Pike et al. | Apr 2007 | B2 |
7229402 | Diaz et al. | Jun 2007 | B2 |
7229437 | Johnson et al. | Jun 2007 | B2 |
7250049 | Roop et al. | Jul 2007 | B2 |
7285116 | De et al. | Oct 2007 | B2 |
7285119 | Stewart et al. | Oct 2007 | B2 |
7326208 | Vanney et al. | Feb 2008 | B2 |
7346379 | Eng et al. | Mar 2008 | B2 |
7367974 | Haemmerich et al. | May 2008 | B2 |
7374567 | Heuser | May 2008 | B2 |
7387629 | Vanney et al. | Jun 2008 | B2 |
7387630 | Mest | Jun 2008 | B2 |
7387636 | Cohn et al. | Jun 2008 | B2 |
7416552 | Paul et al. | Aug 2008 | B2 |
7419477 | Simpson et al. | Sep 2008 | B2 |
7419489 | Vanney et al. | Sep 2008 | B2 |
7422591 | Phan | Sep 2008 | B2 |
7429261 | Kunis et al. | Sep 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7513896 | Orszulak | Apr 2009 | B2 |
7527625 | Knight et al. | May 2009 | B2 |
7578816 | Boveja et al. | Aug 2009 | B2 |
7588567 | Boveja et al. | Sep 2009 | B2 |
7623899 | Worley et al. | Nov 2009 | B2 |
7678108 | Chrisitian et al. | Mar 2010 | B2 |
7681579 | Schwartz | Mar 2010 | B2 |
7771421 | Stewart et al. | Aug 2010 | B2 |
7805182 | Weese et al. | Sep 2010 | B2 |
7842031 | Abboud et al. | Nov 2010 | B2 |
7850642 | Moll et al. | Dec 2010 | B2 |
7850685 | Kunis et al. | Dec 2010 | B2 |
7857808 | Oral et al. | Dec 2010 | B2 |
7857809 | Drysen | Dec 2010 | B2 |
7869865 | Govari et al. | Jan 2011 | B2 |
7896873 | Hiller et al. | Mar 2011 | B2 |
7917211 | Zacouto | Mar 2011 | B2 |
7918819 | Karmarkar et al. | Apr 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7922714 | Stevens-Wright | Apr 2011 | B2 |
7955827 | Rubinsky et al. | Jun 2011 | B2 |
8048067 | Davalos et al. | Nov 2011 | B2 |
8048072 | Verin et al. | Nov 2011 | B2 |
8100895 | Panos et al. | Jan 2012 | B2 |
8100900 | Prinz et al. | Jan 2012 | B2 |
8108069 | Stahler et al. | Jan 2012 | B2 |
8133220 | Lee et al. | Mar 2012 | B2 |
8137342 | Crossman | Mar 2012 | B2 |
8145289 | Calabro′ et al. | Mar 2012 | B2 |
8147486 | Honour et al. | Apr 2012 | B2 |
8160690 | Wilfley et al. | Apr 2012 | B2 |
8175680 | Panescu | May 2012 | B2 |
8182477 | Orszulak et al. | May 2012 | B2 |
8206384 | Falwell et al. | Jun 2012 | B2 |
8206385 | Stangenes et al. | Jun 2012 | B2 |
8216221 | Ibrahim et al. | Jul 2012 | B2 |
8221411 | Francischelli et al. | Jul 2012 | B2 |
8226648 | Paul et al. | Jul 2012 | B2 |
8228065 | Wirtz et al. | Jul 2012 | B2 |
8235986 | Kulesa et al. | Aug 2012 | B2 |
8235988 | Davis et al. | Aug 2012 | B2 |
8251986 | Chornenky et al. | Aug 2012 | B2 |
8282631 | Davalos et al. | Oct 2012 | B2 |
8287532 | Carroll et al. | Oct 2012 | B2 |
8414508 | Thapliyal et al. | Apr 2013 | B2 |
8430875 | Ibrahim et al. | Apr 2013 | B2 |
8433394 | Harlev et al. | Apr 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8454594 | Demarais et al. | Jun 2013 | B2 |
8463368 | Harlev et al. | Jun 2013 | B2 |
8475450 | Govari et al. | Jul 2013 | B2 |
8486063 | Werneth et al. | Jul 2013 | B2 |
8500733 | Watson | Aug 2013 | B2 |
8535304 | Sklar et al. | Sep 2013 | B2 |
8538501 | Venkatachalam et al. | Sep 2013 | B2 |
8562588 | Hobbs et al. | Oct 2013 | B2 |
8568406 | Harlev et al. | Oct 2013 | B2 |
8568410 | Vakharia et al. | Oct 2013 | B2 |
8571635 | McGee | Oct 2013 | B2 |
8571647 | Harlev et al. | Oct 2013 | B2 |
8579897 | Vakharia et al. | Nov 2013 | B2 |
8585695 | Shih | Nov 2013 | B2 |
8588885 | Hall et al. | Nov 2013 | B2 |
8597288 | Christian | Dec 2013 | B2 |
8608735 | Govari et al. | Dec 2013 | B2 |
8628522 | Ibrahim et al. | Jan 2014 | B2 |
8632534 | Pearson et al. | Jan 2014 | B2 |
8647338 | Chornenky et al. | Feb 2014 | B2 |
8708952 | Cohen et al. | Apr 2014 | B2 |
8734442 | Cao et al. | May 2014 | B2 |
8771267 | Kunis et al. | Jul 2014 | B2 |
8795310 | Fung et al. | Aug 2014 | B2 |
8808273 | Caples et al. | Aug 2014 | B2 |
8808281 | Emmons et al. | Aug 2014 | B2 |
8834461 | Werneth et al. | Sep 2014 | B2 |
8834464 | Stewart et al. | Sep 2014 | B2 |
8868169 | Narayan et al. | Oct 2014 | B2 |
8876817 | Avitall et al. | Nov 2014 | B2 |
8880195 | Azure | Nov 2014 | B2 |
8886309 | Luther et al. | Nov 2014 | B2 |
8903488 | Callas et al. | Dec 2014 | B2 |
8920411 | Gelbart et al. | Dec 2014 | B2 |
8926589 | Govari | Jan 2015 | B2 |
8932287 | Gelbart et al. | Jan 2015 | B2 |
8945117 | Bencini | Feb 2015 | B2 |
8979841 | Kunis et al. | Mar 2015 | B2 |
8986278 | Fung et al. | Mar 2015 | B2 |
8996091 | De et al. | Mar 2015 | B2 |
9002442 | Harley et al. | Apr 2015 | B2 |
9005189 | Davalos et al. | Apr 2015 | B2 |
9005194 | Oral et al. | Apr 2015 | B2 |
9011425 | Fischer et al. | Apr 2015 | B2 |
9044245 | Condie et al. | Jun 2015 | B2 |
9055959 | Vaska et al. | Jun 2015 | B2 |
9072518 | Swanson | Jul 2015 | B2 |
9078667 | Besser et al. | Jul 2015 | B2 |
9101374 | Hoch et al. | Aug 2015 | B1 |
9113911 | Sherman | Aug 2015 | B2 |
9119533 | Ghaffari | Sep 2015 | B2 |
9119634 | Gelbart et al. | Sep 2015 | B2 |
9131897 | Harada et al. | Sep 2015 | B2 |
9155590 | Mathur | Oct 2015 | B2 |
9162037 | Belson et al. | Oct 2015 | B2 |
9179972 | Olson | Nov 2015 | B2 |
9186481 | Avitall et al. | Nov 2015 | B2 |
9192769 | Donofrio et al. | Nov 2015 | B2 |
9204916 | Lalonde | Dec 2015 | B2 |
9211405 | Mahapatra et al. | Dec 2015 | B2 |
9216055 | Spence et al. | Dec 2015 | B2 |
9233248 | Luther et al. | Jan 2016 | B2 |
9237926 | Nollert et al. | Jan 2016 | B2 |
9262252 | Kirkpatrick et al. | Feb 2016 | B2 |
9277957 | Long et al. | Mar 2016 | B2 |
9282910 | Narayan et al. | Mar 2016 | B2 |
9289258 | Cohen | Mar 2016 | B2 |
9289606 | Paul et al. | Mar 2016 | B2 |
9295516 | Pearson et al. | Mar 2016 | B2 |
9301801 | Scheib | Apr 2016 | B2 |
9351789 | Novichenok et al. | May 2016 | B2 |
9375268 | Long | Jun 2016 | B2 |
9387031 | Stewart et al. | Jul 2016 | B2 |
9414881 | Callas et al. | Aug 2016 | B2 |
9468495 | Kunis et al. | Oct 2016 | B2 |
9474486 | Eliason et al. | Oct 2016 | B2 |
9474574 | Brahim et al. | Oct 2016 | B2 |
9480525 | Lopes et al. | Nov 2016 | B2 |
9486272 | Bonyak et al. | Nov 2016 | B2 |
9486273 | Lopes et al. | Nov 2016 | B2 |
9492227 | Lopes et al. | Nov 2016 | B2 |
9492228 | Lopes et al. | Nov 2016 | B2 |
9510888 | Lalonde | Dec 2016 | B2 |
9517103 | Panescu et al. | Dec 2016 | B2 |
9526573 | Lopes et al. | Dec 2016 | B2 |
9532831 | Reinders et al. | Jan 2017 | B2 |
9539010 | Gagner et al. | Jan 2017 | B2 |
9554848 | Stewart et al. | Jan 2017 | B2 |
9554851 | Sklar et al. | Jan 2017 | B2 |
9700368 | Callas et al. | Jul 2017 | B2 |
9724170 | Mickelsen | Aug 2017 | B2 |
9757193 | Zarins et al. | Sep 2017 | B2 |
9782099 | Williams et al. | Oct 2017 | B2 |
9795442 | Salahieh et al. | Oct 2017 | B2 |
9801681 | Laske et al. | Oct 2017 | B2 |
9808304 | Lalonde | Nov 2017 | B2 |
9861802 | Mickelsen | Jan 2018 | B2 |
9913685 | Clark et al. | Mar 2018 | B2 |
9931487 | Quinn et al. | Apr 2018 | B2 |
9987081 | Bowers et al. | Jun 2018 | B1 |
9999465 | Long et al. | Jun 2018 | B2 |
10010368 | Laske et al. | Jul 2018 | B2 |
10016232 | Bowers et al. | Jul 2018 | B1 |
10130423 | Viswanathan et al. | Nov 2018 | B1 |
10172673 | Viswanathan et al. | Jan 2019 | B2 |
10194818 | Williams et al. | Feb 2019 | B2 |
10285755 | Stewart et al. | May 2019 | B2 |
10322286 | Viswanathan et al. | Jun 2019 | B2 |
10433906 | Mickelsen | Oct 2019 | B2 |
10433908 | Viswanathan et al. | Oct 2019 | B2 |
10512505 | Viswanathan | Dec 2019 | B2 |
10512779 | Viswanathan et al. | Dec 2019 | B2 |
10517672 | Long | Dec 2019 | B2 |
10617467 | Viswanathan et al. | Apr 2020 | B2 |
10660702 | Viswanathan et al. | May 2020 | B2 |
20010000791 | Suorsa et al. | May 2001 | A1 |
20010007070 | Stewart et al. | Jul 2001 | A1 |
20010044624 | Seraj et al. | Nov 2001 | A1 |
20020022839 | Stewart et al. | Feb 2002 | A1 |
20020052602 | Wang et al. | May 2002 | A1 |
20020058933 | Christopherson et al. | May 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020087169 | Brock et al. | Jul 2002 | A1 |
20020091384 | Hooven et al. | Jul 2002 | A1 |
20020095176 | Prestel | Jul 2002 | A1 |
20020111618 | Stewart et al. | Aug 2002 | A1 |
20020156526 | Hlavka et al. | Oct 2002 | A1 |
20020161323 | Miller et al. | Oct 2002 | A1 |
20020169445 | Jain et al. | Nov 2002 | A1 |
20020177765 | Bowe et al. | Nov 2002 | A1 |
20020183638 | Swanson | Dec 2002 | A1 |
20030014098 | Quijano et al. | Jan 2003 | A1 |
20030018374 | Paulos | Jan 2003 | A1 |
20030023287 | Edwards et al. | Jan 2003 | A1 |
20030028189 | Woloszko et al. | Feb 2003 | A1 |
20030050637 | Maguire et al. | Mar 2003 | A1 |
20030060856 | Chornenky et al. | Mar 2003 | A1 |
20030114849 | Ryan | Jun 2003 | A1 |
20030125729 | Hooven et al. | Jul 2003 | A1 |
20030130598 | Manning et al. | Jul 2003 | A1 |
20030130711 | Pearson et al. | Jul 2003 | A1 |
20030204161 | Ferek-Petric | Oct 2003 | A1 |
20030229379 | Ramsey | Dec 2003 | A1 |
20040039382 | Kroll et al. | Feb 2004 | A1 |
20040049181 | Stewart et al. | Mar 2004 | A1 |
20040049182 | Koblish et al. | Mar 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040082948 | Stewart et al. | Apr 2004 | A1 |
20040087939 | Eggers et al. | May 2004 | A1 |
20040111087 | Stern et al. | Jun 2004 | A1 |
20040199157 | Palanker et al. | Oct 2004 | A1 |
20040231683 | Eng et al. | Nov 2004 | A1 |
20040236360 | Cohn et al. | Nov 2004 | A1 |
20040254607 | Wittenberger et al. | Dec 2004 | A1 |
20040267337 | Hayzelden | Dec 2004 | A1 |
20050033282 | Hooven | Feb 2005 | A1 |
20050187545 | Hooven et al. | Aug 2005 | A1 |
20050222632 | Obino | Oct 2005 | A1 |
20050251130 | Boveja et al. | Nov 2005 | A1 |
20050261672 | Deem et al. | Nov 2005 | A1 |
20060009755 | Sra | Jan 2006 | A1 |
20060009759 | Chrisitian et al. | Jan 2006 | A1 |
20060015095 | Desinger et al. | Jan 2006 | A1 |
20060015165 | Bertolero et al. | Jan 2006 | A1 |
20060024359 | Walker et al. | Feb 2006 | A1 |
20060058781 | Long | Mar 2006 | A1 |
20060111702 | Oral et al. | May 2006 | A1 |
20060142801 | Demarais et al. | Jun 2006 | A1 |
20060161148 | Behnke | Jul 2006 | A1 |
20060167448 | Kozel | Jul 2006 | A1 |
20060217703 | Chornenky et al. | Sep 2006 | A1 |
20060241734 | Marshall et al. | Oct 2006 | A1 |
20060264752 | Rubinsky et al. | Nov 2006 | A1 |
20060270900 | Chin et al. | Nov 2006 | A1 |
20060287648 | Schwartz | Dec 2006 | A1 |
20060293730 | Rubinsky et al. | Dec 2006 | A1 |
20060293731 | Rubinsky et al. | Dec 2006 | A1 |
20070005053 | Dando | Jan 2007 | A1 |
20070021744 | Creighton | Jan 2007 | A1 |
20070060989 | Deem et al. | Mar 2007 | A1 |
20070066972 | Ormsby et al. | Mar 2007 | A1 |
20070129721 | Phan et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070156135 | Rubinsky et al. | Jul 2007 | A1 |
20070167740 | Grunewald et al. | Jul 2007 | A1 |
20070167940 | Stevens-Wright | Jul 2007 | A1 |
20070173878 | Heuser | Jul 2007 | A1 |
20070208329 | Ward et al. | Sep 2007 | A1 |
20070225589 | Viswanathan | Sep 2007 | A1 |
20070249923 | Keenan | Oct 2007 | A1 |
20070260223 | Scheibe et al. | Nov 2007 | A1 |
20070270792 | Hennemann et al. | Nov 2007 | A1 |
20080009855 | Hamou | Jan 2008 | A1 |
20080033426 | Machell | Feb 2008 | A1 |
20080065061 | Viswanathan | Mar 2008 | A1 |
20080086120 | Mirza et al. | Apr 2008 | A1 |
20080091195 | Sliwa et al. | Apr 2008 | A1 |
20080103545 | Bolea et al. | May 2008 | A1 |
20080132885 | Rubinsky et al. | Jun 2008 | A1 |
20080161789 | Thao et al. | Jul 2008 | A1 |
20080172048 | Martin et al. | Jul 2008 | A1 |
20080200913 | Viswanathan | Aug 2008 | A1 |
20080208118 | Goldman | Aug 2008 | A1 |
20080243214 | Koblish | Oct 2008 | A1 |
20080281322 | Sherman et al. | Nov 2008 | A1 |
20080300574 | Belson et al. | Dec 2008 | A1 |
20080300588 | Groth et al. | Dec 2008 | A1 |
20090024084 | Khosla et al. | Jan 2009 | A1 |
20090048591 | Ibrahim et al. | Feb 2009 | A1 |
20090062788 | Long et al. | Mar 2009 | A1 |
20090076496 | Azure | Mar 2009 | A1 |
20090076500 | Azure | Mar 2009 | A1 |
20090105654 | Kurth et al. | Apr 2009 | A1 |
20090138009 | Viswanathan et al. | May 2009 | A1 |
20090149917 | Whitehurst et al. | Jun 2009 | A1 |
20090163905 | Winkler et al. | Jun 2009 | A1 |
20090228003 | Sinelnikov | Sep 2009 | A1 |
20090240248 | Deford et al. | Sep 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090281477 | Mikus et al. | Nov 2009 | A1 |
20090306651 | Schneider | Dec 2009 | A1 |
20100004623 | Hamilton et al. | Jan 2010 | A1 |
20100023004 | Francischelli et al. | Jan 2010 | A1 |
20100137861 | Soroff et al. | Jun 2010 | A1 |
20100185140 | Kassab et al. | Jul 2010 | A1 |
20100185186 | Longoria | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100191232 | Boveda | Jul 2010 | A1 |
20100241185 | Mahapatra et al. | Sep 2010 | A1 |
20100261994 | Davalos et al. | Oct 2010 | A1 |
20100274238 | Klimovitch | Oct 2010 | A1 |
20100280513 | Juergen et al. | Nov 2010 | A1 |
20100280539 | Miyoshi et al. | Nov 2010 | A1 |
20100292687 | Kauphusman et al. | Nov 2010 | A1 |
20100312096 | Guttman et al. | Dec 2010 | A1 |
20100312300 | Ryu et al. | Dec 2010 | A1 |
20110028962 | Werneth et al. | Feb 2011 | A1 |
20110028964 | Edwards | Feb 2011 | A1 |
20110040199 | Hopenfeld | Feb 2011 | A1 |
20110098694 | Long | Apr 2011 | A1 |
20110106221 | Neal et al. | May 2011 | A1 |
20110130708 | Perry et al. | Jun 2011 | A1 |
20110144524 | Fish et al. | Jun 2011 | A1 |
20110144633 | Govari | Jun 2011 | A1 |
20110160785 | Mori et al. | Jun 2011 | A1 |
20110190659 | Long et al. | Aug 2011 | A1 |
20110190727 | Edmunds et al. | Aug 2011 | A1 |
20110213231 | Hall et al. | Sep 2011 | A1 |
20110276047 | Sklar et al. | Nov 2011 | A1 |
20110276075 | Fung et al. | Nov 2011 | A1 |
20110288544 | Verin et al. | Nov 2011 | A1 |
20110288547 | Morgan et al. | Nov 2011 | A1 |
20110313417 | De et al. | Dec 2011 | A1 |
20120029512 | Willard et al. | Feb 2012 | A1 |
20120046570 | Villegas et al. | Feb 2012 | A1 |
20120053581 | Wittkampf et al. | Mar 2012 | A1 |
20120059255 | Paul et al. | Mar 2012 | A1 |
20120071872 | Rubinsky et al. | Mar 2012 | A1 |
20120078320 | Schotzko et al. | Mar 2012 | A1 |
20120078343 | Fish | Mar 2012 | A1 |
20120089089 | Swain et al. | Apr 2012 | A1 |
20120095459 | Callas et al. | Apr 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120158021 | Morrill | Jun 2012 | A1 |
20120165667 | Altmann et al. | Jun 2012 | A1 |
20120172859 | Condie et al. | Jul 2012 | A1 |
20120172867 | Ryu et al. | Jul 2012 | A1 |
20120197100 | Razavi et al. | Aug 2012 | A1 |
20120209260 | Lambert et al. | Aug 2012 | A1 |
20120220998 | Long et al. | Aug 2012 | A1 |
20120265198 | Crow et al. | Oct 2012 | A1 |
20120283582 | Mahapatra et al. | Nov 2012 | A1 |
20120303019 | Zhao et al. | Nov 2012 | A1 |
20120310052 | Mahapatra et al. | Dec 2012 | A1 |
20120310230 | Willis | Dec 2012 | A1 |
20120310237 | Swanson | Dec 2012 | A1 |
20120316557 | Sartor et al. | Dec 2012 | A1 |
20130030430 | Stewart et al. | Jan 2013 | A1 |
20130060247 | Sklar et al. | Mar 2013 | A1 |
20130060248 | Sklar et al. | Mar 2013 | A1 |
20130079768 | De et al. | Mar 2013 | A1 |
20130090651 | Smith | Apr 2013 | A1 |
20130096655 | Moffitt et al. | Apr 2013 | A1 |
20130103027 | Sklar et al. | Apr 2013 | A1 |
20130103064 | Arenson et al. | Apr 2013 | A1 |
20130131662 | Wittkampf | May 2013 | A1 |
20130158538 | Govari | Jun 2013 | A1 |
20130158621 | Ding et al. | Jun 2013 | A1 |
20130172715 | Just et al. | Jul 2013 | A1 |
20130172864 | Ibrahim et al. | Jul 2013 | A1 |
20130172875 | Govari et al. | Jul 2013 | A1 |
20130184702 | Neal et al. | Jul 2013 | A1 |
20130218157 | Callas et al. | Aug 2013 | A1 |
20130226174 | Ibrahim et al. | Aug 2013 | A1 |
20130237984 | Sklar | Sep 2013 | A1 |
20130253415 | Sano et al. | Sep 2013 | A1 |
20130296679 | Condie et al. | Nov 2013 | A1 |
20130310829 | Cohen | Nov 2013 | A1 |
20130317385 | Sklar et al. | Nov 2013 | A1 |
20130331831 | Werneth et al. | Dec 2013 | A1 |
20130338467 | Grasse et al. | Dec 2013 | A1 |
20140005664 | Govari et al. | Jan 2014 | A1 |
20140024911 | Harlev et al. | Jan 2014 | A1 |
20140039288 | Hue-Teh | Feb 2014 | A1 |
20140051993 | McGee | Feb 2014 | A1 |
20140052118 | Laske et al. | Feb 2014 | A1 |
20140052126 | Long et al. | Feb 2014 | A1 |
20140052216 | Long et al. | Feb 2014 | A1 |
20140058377 | Deem et al. | Feb 2014 | A1 |
20140081113 | Cohen et al. | Mar 2014 | A1 |
20140100563 | Govari et al. | Apr 2014 | A1 |
20140107644 | Falwell et al. | Apr 2014 | A1 |
20140142408 | De et al. | May 2014 | A1 |
20140148804 | Ward et al. | May 2014 | A1 |
20140163480 | Govari et al. | Jun 2014 | A1 |
20140163546 | Govari et al. | Jun 2014 | A1 |
20140171942 | Werneth et al. | Jun 2014 | A1 |
20140180035 | Anderson | Jun 2014 | A1 |
20140187916 | Clark et al. | Jul 2014 | A1 |
20140194716 | Diep et al. | Jul 2014 | A1 |
20140194867 | Fish et al. | Jul 2014 | A1 |
20140200567 | Cox et al. | Jul 2014 | A1 |
20140235986 | Harlev et al. | Aug 2014 | A1 |
20140235988 | Ghosh | Aug 2014 | A1 |
20140235989 | Wodlinger et al. | Aug 2014 | A1 |
20140243851 | Cohen et al. | Aug 2014 | A1 |
20140253140 | Gilbert | Sep 2014 | A1 |
20140276760 | Bonyak et al. | Sep 2014 | A1 |
20140276782 | Paskar | Sep 2014 | A1 |
20140276791 | Ku et al. | Sep 2014 | A1 |
20140288556 | Ibrahim et al. | Sep 2014 | A1 |
20140303721 | Fung et al. | Oct 2014 | A1 |
20140343549 | Spear et al. | Nov 2014 | A1 |
20140364797 | Schoenbach | Dec 2014 | A1 |
20140364845 | Rashidi | Dec 2014 | A1 |
20140371613 | Narayan et al. | Dec 2014 | A1 |
20150005767 | Werneth et al. | Jan 2015 | A1 |
20150011995 | Avitall et al. | Jan 2015 | A1 |
20150066108 | Shi et al. | Mar 2015 | A1 |
20150119674 | Fischell et al. | Apr 2015 | A1 |
20150126840 | Thakur et al. | May 2015 | A1 |
20150133914 | Koblish | May 2015 | A1 |
20150138977 | Dacosta | May 2015 | A1 |
20150141978 | Subramaniam et al. | May 2015 | A1 |
20150141982 | Lee | May 2015 | A1 |
20150142041 | Kendale et al. | May 2015 | A1 |
20150148796 | Bencini | May 2015 | A1 |
20150150472 | Harlev et al. | Jun 2015 | A1 |
20150157402 | Kunis et al. | Jun 2015 | A1 |
20150157412 | Wallace et al. | Jun 2015 | A1 |
20150164584 | Davalos et al. | Jun 2015 | A1 |
20150173824 | Davalos et al. | Jun 2015 | A1 |
20150173828 | Avitall | Jun 2015 | A1 |
20150174404 | Rousso et al. | Jun 2015 | A1 |
20150182740 | Mickelsen | Jul 2015 | A1 |
20150196217 | Harlev et al. | Jul 2015 | A1 |
20150223726 | Harlev et al. | Aug 2015 | A1 |
20150230699 | Berul et al. | Aug 2015 | A1 |
20150258344 | Tandri et al. | Sep 2015 | A1 |
20150265342 | Long et al. | Sep 2015 | A1 |
20150265344 | Aktas et al. | Sep 2015 | A1 |
20150272656 | Chen | Oct 2015 | A1 |
20150272664 | Cohen | Oct 2015 | A9 |
20150272667 | Govari et al. | Oct 2015 | A1 |
20150282729 | Harlev et al. | Oct 2015 | A1 |
20150289923 | Davalos et al. | Oct 2015 | A1 |
20150304879 | Dacosta | Oct 2015 | A1 |
20150320481 | Cosman et al. | Nov 2015 | A1 |
20150321021 | Tandri et al. | Nov 2015 | A1 |
20150342532 | Basu et al. | Dec 2015 | A1 |
20150343212 | Rousso et al. | Dec 2015 | A1 |
20150351836 | Prutchi | Dec 2015 | A1 |
20150359583 | Swanson | Dec 2015 | A1 |
20160000500 | Salahieh et al. | Jan 2016 | A1 |
20160008061 | Fung et al. | Jan 2016 | A1 |
20160008065 | Gliner et al. | Jan 2016 | A1 |
20160029960 | Toth et al. | Feb 2016 | A1 |
20160038772 | Thapliyal et al. | Feb 2016 | A1 |
20160051204 | Harlev et al. | Feb 2016 | A1 |
20160051324 | Stewart et al. | Feb 2016 | A1 |
20160058493 | Neal et al. | Mar 2016 | A1 |
20160058506 | Spence et al. | Mar 2016 | A1 |
20160066993 | Avitall et al. | Mar 2016 | A1 |
20160074679 | Thapliyal et al. | Mar 2016 | A1 |
20160095531 | Narayan et al. | Apr 2016 | A1 |
20160095642 | Deno et al. | Apr 2016 | A1 |
20160095653 | Lambert et al. | Apr 2016 | A1 |
20160100797 | Mahapatra et al. | Apr 2016 | A1 |
20160100879 | Long | Apr 2016 | A1 |
20160100884 | Fay et al. | Apr 2016 | A1 |
20160106498 | Highsmith et al. | Apr 2016 | A1 |
20160106500 | Olson | Apr 2016 | A1 |
20160113709 | Maor | Apr 2016 | A1 |
20160113712 | Cheung et al. | Apr 2016 | A1 |
20160120564 | Kirkpatrick et al. | May 2016 | A1 |
20160128770 | Afonso et al. | May 2016 | A1 |
20160166167 | Narayan et al. | Jun 2016 | A1 |
20160166310 | Stewart et al. | Jun 2016 | A1 |
20160166311 | Long et al. | Jun 2016 | A1 |
20160174865 | Stewart et al. | Jun 2016 | A1 |
20160183877 | Williams et al. | Jun 2016 | A1 |
20160184003 | Srimathveeravalli et al. | Jun 2016 | A1 |
20160184004 | Hull et al. | Jun 2016 | A1 |
20160213282 | Leo et al. | Jul 2016 | A1 |
20160220307 | Miller et al. | Aug 2016 | A1 |
20160235470 | Callas et al. | Aug 2016 | A1 |
20160249972 | Klink | Sep 2016 | A1 |
20160256682 | Paul et al. | Sep 2016 | A1 |
20160287314 | Arena et al. | Oct 2016 | A1 |
20160310211 | Long | Oct 2016 | A1 |
20160324564 | Gerlach et al. | Nov 2016 | A1 |
20160324573 | Mickelson et al. | Nov 2016 | A1 |
20160331441 | Konings | Nov 2016 | A1 |
20160331459 | Townley et al. | Nov 2016 | A1 |
20160338770 | Bar-Tal et al. | Nov 2016 | A1 |
20160354142 | Pearson et al. | Dec 2016 | A1 |
20160361109 | Weaver et al. | Dec 2016 | A1 |
20170001016 | De Ridder | Jan 2017 | A1 |
20170035499 | Stewart et al. | Feb 2017 | A1 |
20170042449 | Deno et al. | Feb 2017 | A1 |
20170042615 | Salahieh et al. | Feb 2017 | A1 |
20170056648 | Syed et al. | Mar 2017 | A1 |
20170065330 | Mickelsen et al. | Mar 2017 | A1 |
20170065339 | Mickelsen | Mar 2017 | A1 |
20170065340 | Long | Mar 2017 | A1 |
20170065343 | Mickelsen | Mar 2017 | A1 |
20170071543 | Basu et al. | Mar 2017 | A1 |
20170095291 | Harrington et al. | Apr 2017 | A1 |
20170105793 | Cao et al. | Apr 2017 | A1 |
20170120048 | He et al. | May 2017 | A1 |
20170146584 | Daw et al. | May 2017 | A1 |
20170151014 | Perfler | Jun 2017 | A1 |
20170151029 | Mickelsen | Jun 2017 | A1 |
20170172654 | Wittkampf et al. | Jun 2017 | A1 |
20170181795 | Debruyne | Jun 2017 | A1 |
20170189097 | Viswanathan et al. | Jul 2017 | A1 |
20170215953 | Long et al. | Aug 2017 | A1 |
20170245928 | Xiao et al. | Aug 2017 | A1 |
20170246455 | Athos et al. | Aug 2017 | A1 |
20170312024 | Harlev et al. | Nov 2017 | A1 |
20170312025 | Harlev et al. | Nov 2017 | A1 |
20170312027 | Harlev et al. | Nov 2017 | A1 |
20170319851 | Athos | Nov 2017 | A1 |
20180001056 | Leeflang et al. | Jan 2018 | A1 |
20180028252 | Lalonde | Feb 2018 | A1 |
20180042674 | Mickelsen | Feb 2018 | A1 |
20180042675 | Long | Feb 2018 | A1 |
20180043153 | Viswanathan et al. | Feb 2018 | A1 |
20180064488 | Long et al. | Mar 2018 | A1 |
20180085160 | Viswanathan et al. | Mar 2018 | A1 |
20180093088 | Mickelsen | Apr 2018 | A1 |
20180133460 | Townley et al. | May 2018 | A1 |
20180161093 | Basu et al. | Jun 2018 | A1 |
20180168511 | Hall et al. | Jun 2018 | A1 |
20180184982 | Basu et al. | Jul 2018 | A1 |
20180193090 | De et al. | Jul 2018 | A1 |
20180200497 | Mickelsen | Jul 2018 | A1 |
20180235496 | Wu et al. | Aug 2018 | A1 |
20180256109 | Wu et al. | Sep 2018 | A1 |
20180280080 | Govari et al. | Oct 2018 | A1 |
20180303488 | Hill | Oct 2018 | A1 |
20180303543 | Stewart et al. | Oct 2018 | A1 |
20180311497 | Viswanathan et al. | Nov 2018 | A1 |
20180344202 | Bar-Tal et al. | Dec 2018 | A1 |
20180344393 | Gruba et al. | Dec 2018 | A1 |
20180360531 | Holmes et al. | Dec 2018 | A1 |
20180360534 | Teplitsky et al. | Dec 2018 | A1 |
20190015007 | Rottmann et al. | Jan 2019 | A1 |
20190015638 | Gruba et al. | Jan 2019 | A1 |
20190030328 | Stewart et al. | Jan 2019 | A1 |
20190046791 | Ebbers et al. | Feb 2019 | A1 |
20190069950 | Viswanathan et al. | Mar 2019 | A1 |
20190076179 | Babkin et al. | Mar 2019 | A1 |
20190125439 | Rohl et al. | May 2019 | A1 |
20190125788 | Gruba et al. | May 2019 | A1 |
20190143106 | Dewitt et al. | May 2019 | A1 |
20190151015 | Viswanathan et al. | May 2019 | A1 |
20190175263 | Altmann et al. | Jun 2019 | A1 |
20190183378 | Mosesov et al. | Jun 2019 | A1 |
20190183567 | Govari et al. | Jun 2019 | A1 |
20190192223 | Rankin | Jun 2019 | A1 |
20190201089 | Waldstreicher et al. | Jul 2019 | A1 |
20190201688 | Olson | Jul 2019 | A1 |
20190209235 | Stewart et al. | Jul 2019 | A1 |
20190223948 | Stewart et al. | Jul 2019 | A1 |
20190231421 | Viswanathan et al. | Aug 2019 | A1 |
20190231425 | Waldstreicher et al. | Aug 2019 | A1 |
20190254735 | Stewart et al. | Aug 2019 | A1 |
20190269912 | Viswanathan et al. | Sep 2019 | A1 |
20190298442 | Ogata et al. | Oct 2019 | A1 |
20190307500 | Byrd et al. | Oct 2019 | A1 |
20190350647 | Ramberg et al. | Nov 2019 | A1 |
20190350649 | Sutermeister et al. | Nov 2019 | A1 |
20200008869 | Byrd | Jan 2020 | A1 |
20200008870 | Gruba et al. | Jan 2020 | A1 |
20200009378 | Stewart et al. | Jan 2020 | A1 |
20200038104 | Mickelsen | Feb 2020 | A1 |
20200046423 | Viswanathan et al. | Feb 2020 | A1 |
20200093539 | Long et al. | Mar 2020 | A1 |
20200129233 | Viswanathan | Apr 2020 | A1 |
20200289827 | Forsyth et al. | Sep 2020 | A1 |
20210393327 | Eyster | Dec 2021 | A1 |
20220133405 | Mickelsen | May 2022 | A1 |
Number | Date | Country |
---|---|---|
741167 | Nov 2001 | AU |
1042990 | Oct 2000 | EP |
1125549 | Aug 2001 | EP |
0797956 | Jun 2003 | EP |
1340469 | Sep 2003 | EP |
1127552 | Jun 2006 | EP |
1803411 | Jul 2007 | EP |
1009303 | Jun 2009 | EP |
2213729 | Aug 2010 | EP |
2382935 | Nov 2011 | EP |
2425871 | Mar 2012 | EP |
2532320 | Dec 2012 | EP |
2587275 | May 2013 | EP |
2663227 | Nov 2013 | EP |
1909678 | Jan 2014 | EP |
2217165 | Mar 2014 | EP |
2376193 | Mar 2014 | EP |
2708181 | Mar 2014 | EP |
2777579 | Sep 2014 | EP |
2777585 | Sep 2014 | EP |
2934307 | Oct 2015 | EP |
3056242 | Aug 2016 | EP |
3111871 | Jan 2017 | EP |
3151773 | Apr 2018 | EP |
06-507797 | Sep 1994 | JP |
2000-508196 | Jul 2000 | JP |
2005-516666 | Jun 2005 | JP |
2006-506184 | Feb 2006 | JP |
2008-538997 | Nov 2008 | JP |
2009-500129 | Jan 2009 | JP |
2011-509158 | Mar 2011 | JP |
2012-050538 | Mar 2012 | JP |
2018-510015 | Apr 2018 | JP |
2018-089431 | Jun 2018 | JP |
2020-516371 | Jun 2020 | JP |
9207622 | May 1992 | WO |
9221278 | Dec 1992 | WO |
9221285 | Dec 1992 | WO |
9407413 | Apr 1994 | WO |
9724073 | Jul 1997 | WO |
9725917 | Jul 1997 | WO |
9737719 | Oct 1997 | WO |
9904851 | Feb 1999 | WO |
9922659 | May 1999 | WO |
9956650 | Nov 1999 | WO |
9959486 | Nov 1999 | WO |
0256782 | Jul 2002 | WO |
0353289 | Jul 2003 | WO |
0365916 | Aug 2003 | WO |
2004045442 | Jun 2004 | WO |
2004086994 | Oct 2004 | WO |
2005046487 | May 2005 | WO |
2006115902 | Nov 2006 | WO |
2007006055 | Jan 2007 | WO |
2007079438 | Jul 2007 | WO |
2009082710 | Jul 2009 | WO |
2009089343 | Jul 2009 | WO |
2009137800 | Nov 2009 | WO |
2010014480 | Feb 2010 | WO |
2011028310 | Mar 2011 | WO |
2011154805 | Dec 2011 | WO |
2012051433 | Apr 2012 | WO |
2012097067 | Jul 2012 | WO |
2012153928 | Nov 2012 | WO |
2013019385 | Feb 2013 | WO |
2014025394 | Feb 2014 | WO |
2014031800 | Feb 2014 | WO |
2014036439 | Mar 2014 | WO |
2014100579 | Jun 2014 | WO |
2014160832 | Oct 2014 | WO |
2015066322 | May 2015 | WO |
2015099786 | Jul 2015 | WO |
2015103530 | Jul 2015 | WO |
2015103574 | Jul 2015 | WO |
2015130824 | Sep 2015 | WO |
2015140741 | Sep 2015 | WO |
2015143327 | Sep 2015 | WO |
2015171921 | Nov 2015 | WO |
2015175944 | Nov 2015 | WO |
2015192018 | Dec 2015 | WO |
2015192027 | Dec 2015 | WO |
2016059027 | Apr 2016 | WO |
2016060983 | Apr 2016 | WO |
2016081650 | May 2016 | WO |
2016090175 | Jun 2016 | WO |
2017093926 | Jun 2017 | WO |
2017119934 | Jul 2017 | WO |
2017120169 | Jul 2017 | WO |
2017192477 | Nov 2017 | WO |
2017192495 | Nov 2017 | WO |
2017201504 | Nov 2017 | WO |
2017218734 | Dec 2017 | WO |
2018005511 | Jan 2018 | WO |
2018106569 | Jun 2018 | WO |
2018200800 | Nov 2018 | WO |
2019023259 | Jan 2019 | WO |
2019023280 | Jan 2019 | WO |
2019035071 | Feb 2019 | WO |
2019133606 | Jul 2019 | WO |
2019133608 | Jul 2019 | WO |
2019136218 | Jul 2019 | WO |
2019181612 | Sep 2019 | WO |
2019234133 | Dec 2019 | WO |
Entry |
---|
Du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013). |
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2022/013512, mailed on May 4, 2022, 12 pages. |
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007]. |
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016). |
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014). |
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014). |
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014). |
Van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015). |
Van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014). |
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011). |
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012). |
Notice of Reasons for Refusal received for Japanese Patent Application No. 2023-545295, mailed on May 21, 2024, 12 pages (6 pages of English Translation and 6 pages of Original Document). |
Number | Date | Country | |
---|---|---|---|
20220233237 A1 | Jul 2022 | US |
Number | Date | Country | |
---|---|---|---|
63142133 | Jan 2021 | US |